View More Posts


The Grand opening event was held on 15th May 2018 and was a great opportunity for the company to not only showcase the new, state-of-the art lab and office spaces but also update the shareholders a...

Read More

Whilst in New York, where she was addressing the 2018 Annual Meeting for the American Psychiatric Association in early May, Baroness Greenfield was able to meet up for a lunch with three...

Read More

ABOUT Neuro Bio

Neuro-Bio is a privately-owned biotech out of Oxford University with a therapeutic focus on neurodegenerative disease. The company has discovered a novel 14 amino acid bioactive peptide (T14) derived from the C terminus of AChE. T14 is neurotoxic in the adult brain and published data shows it to be a potential key driver of neurodegeneration. This new distinct mechanism is being exploited by Neuro-Bio to discover oral drugs to treat Alzheimer's disease. T14 can also be measured in blood and Neuro-Bio is developing this biomarker as a companion diagnostic.

Dr Richard Mohs


"I compliment you on development of this novel and innovative approach to AD…the idea of linking known facts about selective neuronal vulnerability with both novel biomarkers and novel therapeutics is really quite exciting and is something completely absent from current approaches focusing heavily on amyloid-beta and tau."

Chief Scientific Officer, Global Alzheimer’s Platform, Nov 2017

Baroness Professor Susan Greenfield, CBE

CEO and Founder

Baroness Greenfield is a British scientist, writer and broadcaster. Susan has published over 200 papers in peer-reviewed journals over the course of her distinguished career. She holds 32 honorary degrees from UK and foreign universities, and has received numerous honours including the Australian Medical Research Society Medal and Legion d’Honneur from the French Government. Susan also has an Honorary Fellowship from the Royal College of Physicians and is a member of the Fellowship of the Royal Society of Edinburgh.

David Fuente

Investor Director

David is an experienced manager and director having been Chairman and CEO of a number of companies across a wide variety of sectors.
He has a Master’s degree from Purdue University.

Dominique Kleyn

Commercial Director

Dominique has experience sitting on a number of Boards, as a non-executive director, across the Healthcare sector. Her skills lie within business development and marketing.
Dominique has an MBA from Imperial University.